Giduxa (Devil's Claw Root Extract)

What Is Giduxa and What Is It Used For?

Quick Answer: Giduxa is a traditional herbal medicinal product containing devil's claw root extract. It is used for the relief of mild joint pain and mild digestive complaints such as bloating, gas, and temporary loss of appetite. Its indications are based on long-standing traditional use rather than clinical trial evidence alone.

Giduxa belongs to the category of traditional herbal medicinal products — a regulatory classification used in the European Union for plant-based medicines with a documented history of at least 30 years of traditional use, including at least 15 years within the EU. This classification means that while the product has not undergone the same rigorous clinical trial process as conventional pharmaceuticals, it has a well-established safety and efficacy profile based on decades of practical experience.

The active ingredient in Giduxa is a dry extract derived from the root of devil's claw (Harpagophytum procumbens DC. and/or Harpagophytum zeyheri Decne.), a plant native to the Kalahari Desert and savannah regions of Southern Africa. Each capsule contains 225 mg of extract, equivalent to approximately 990–1,125 mg of dried devil's claw root. The extraction solvent used is 60% ethanol (v/v).

Devil's claw has been used for centuries by the indigenous San and Khoi peoples of Southern Africa as a traditional remedy for pain, fever, and digestive ailments. The plant was introduced to European herbal medicine in the early 20th century and has since become one of the most widely used herbal anti-inflammatory agents on the continent. The European Medicines Agency (EMA) Committee on Herbal Medicinal Products (HMPC) has published a comprehensive monograph on Harpagophytum procumbens, recognizing its traditional use for musculoskeletal pain and digestive disorders.

Mechanism of Action

The pharmacological activity of devil's claw root is primarily attributed to a group of compounds known as iridoid glycosides, with harpagoside being the most studied and quantified marker compound. Research has identified several mechanisms through which these compounds may exert their therapeutic effects:

• Anti-inflammatory activity: Harpagoside and related compounds have been shown to inhibit the expression of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), key enzymes involved in the inflammatory cascade. They also modulate pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6).
• Analgesic properties: Studies suggest that devil's claw extract may reduce pain perception through both peripheral anti-inflammatory mechanisms and central analgesic pathways, although the precise central mechanisms remain under investigation.
• Digestive effects: The bitter compounds in devil's claw root, particularly the iridoid glycosides, act as bitter stimulants that promote the secretion of digestive enzymes and gastric acid, improving overall digestive function and stimulating appetite.
• Antioxidant properties: Devil's claw extract contains phenolic compounds and flavonoids that contribute to its antioxidant capacity, which may help protect joint tissues from oxidative damage.

Clinical Evidence

Several clinical studies have evaluated the efficacy of devil's claw extract in musculoskeletal conditions. A systematic review published in Phytomedicine analyzed data from multiple randomized controlled trials and concluded that Harpagophytum preparations with adequate harpagoside content (at least 50 mg daily) demonstrated clinically meaningful improvements in pain and mobility in patients with osteoarthritis and low back pain. The European Scientific Cooperative on Phytotherapy (ESCOP) and the World Health Organization (WHO) have both recognized devil's claw root for its traditional use in musculoskeletal and digestive disorders.

It is important to note that while the evidence supports traditional use, the quality and design of many earlier studies have methodological limitations. More recent, high-quality clinical trials continue to investigate the full therapeutic potential of devil's claw extract in various inflammatory conditions.

What Should You Know Before Taking Giduxa?

Quick Answer: Do not take Giduxa if you are allergic to devil's claw, peanuts, or soy, or if you have stomach or intestinal ulcers. Consult a doctor before use if you have gallstones. Not recommended for children under 18 or during pregnancy and breastfeeding.

Contraindications

There are specific situations in which Giduxa should not be used. Understanding these contraindications is essential for safe use:

Warnings and Precautions

Before starting Giduxa, it is important to speak with your healthcare provider if any of the following conditions apply to you:

• Joint pain accompanied by swelling, redness, or fever: These symptoms may indicate an inflammatory joint condition (such as rheumatoid arthritis, gout, or septic arthritis) that requires medical diagnosis and specific treatment. Self-medication with herbal products may delay appropriate care in these situations.
• Gallstone problems (cholelithiasis): Devil's claw has choleretic (bile-stimulating) properties that may trigger biliary colic in individuals with gallstones. If you have a known history of gallstone disease, consult your doctor before using this product.
• Diabetes: While not specifically contraindicated, some evidence suggests devil's claw may affect blood glucose levels. Individuals with diabetes should monitor their blood sugar more closely when starting this medication.

If your symptoms worsen during treatment with Giduxa, discontinue use and consult a healthcare professional promptly. Joint pain that persists beyond 4 weeks or digestive complaints lasting more than 2 weeks warrant medical evaluation to rule out more serious underlying conditions.

Children and Adolescents

Giduxa is not recommended for children and adolescents under 18 years of age due to insufficient safety and efficacy data in this population. The traditional use documentation does not include adequate information about the use of devil's claw products in pediatric patients. If a child or adolescent experiences joint pain or digestive complaints, consult a pediatric healthcare provider for age-appropriate diagnosis and treatment.

Pregnancy and Breastfeeding

Due to insufficient safety data, Giduxa is not recommended during pregnancy or while breastfeeding. The potential effects of devil's claw extract on fertility, fetal development, and lactation have not been adequately studied. Some animal studies have suggested possible uterotonic activity, meaning the herb could theoretically affect uterine contractions, though this has not been confirmed in humans at therapeutic doses.

If you are pregnant, breastfeeding, think you may be pregnant, or are planning to have a baby, consult your doctor or pharmacist before taking this medicine. This precautionary advice aligns with the EMA HMPC assessment, which does not recommend the use of Harpagophytum preparations during pregnancy and lactation.

Allergen Information

Driving and Operating Machinery

Giduxa has no known or negligible effect on the ability to drive or operate machinery. However, as with any medication, you are responsible for assessing your own fitness to drive or perform tasks requiring alertness. If you experience dizziness or other side effects that could impair your judgment, refrain from these activities and consult your healthcare provider.

How Does Giduxa Interact with Other Drugs?

Quick Answer: The possible effects of taking Giduxa together with other medicines have not been formally studied. Always inform your healthcare provider about all medications and supplements you are currently taking, including herbal products.

Currently, there are no formally documented drug interactions for Giduxa from controlled clinical studies. However, based on the known pharmacological properties of devil's claw extract and case reports from the wider scientific literature, several theoretical interactions should be considered:

Potential Interactions to Be Aware Of

Food, Drink, and Alcohol Interactions

There are no known interactions between Giduxa and food, drinks, or alcohol. The capsules can be taken with or without food, though swallowing with a glass of water is recommended to facilitate absorption. While no specific alcohol interaction has been identified, it is generally advisable to consume alcohol in moderation when taking any medication, as alcohol may independently affect liver function and gastrointestinal health.

What Is the Correct Dosage of Giduxa?

Quick Answer: Adults should take 2 capsules twice daily, swallowed with a glass of water. The maximum daily dose is 4 capsules. Do not exceed this dose. Giduxa is not recommended for children under 18.

Always take Giduxa exactly as described in the product information or as directed by your healthcare provider. If you are unsure about the correct dosage, consult your doctor, pharmacist, or other healthcare professional.

Adults

The daily dose of 4 capsules provides approximately 900 mg of devil's claw root dry extract, equivalent to about 3,960–4,500 mg of dried root material. This dosage aligns with the range recommended by the EMA HMPC monograph for traditional use of Harpagophytum preparations. The therapeutic effects of devil's claw may take several days to become noticeable, as the anti-inflammatory mechanisms build up over time.

Children and Adolescents

Elderly

Missed Dose

If you forget to take a dose of Giduxa, simply take the next dose at the usual time. Do not take a double dose to make up for a missed one. Because devil's claw works through gradual accumulation of its anti-inflammatory effects, missing a single dose is unlikely to significantly affect the overall therapeutic outcome. However, for optimal results, try to take the capsules at regular intervals.

Overdose

If you have taken significantly more Giduxa than recommended, or if a child has accidentally ingested the capsules, contact your healthcare provider, hospital emergency department, or local poison control center immediately for risk assessment and guidance.

While severe overdose toxicity data for devil's claw is limited, excessive intake could potentially cause gastrointestinal distress, including nausea, vomiting, diarrhea, and abdominal pain. If symptoms develop after suspected overdose, seek medical attention promptly.

Stopping Treatment

You may stop taking Giduxa at any time without needing to taper the dose. There are no known withdrawal effects associated with discontinuation of devil's claw preparations. If you experience a return of symptoms after stopping, you may resume treatment or consult your healthcare provider about alternative approaches.

What Are the Side Effects of Giduxa?

Quick Answer: Reported side effects include gastrointestinal symptoms (diarrhea, nausea, vomiting, abdominal pain), headache, dizziness, and allergic reactions (rash, urticaria, facial swelling). The frequency of these effects is not precisely known but they are generally considered uncommon.

Like all medicines, Giduxa can cause side effects, although not everyone will experience them. Devil's claw preparations are generally well tolerated when used at recommended doses. The side effects listed below have been reported during post-marketing surveillance and from clinical studies. Because the exact frequency of occurrence has not been determined from large-scale studies, these are classified as "frequency not known."

The gastrointestinal side effects are the most commonly reported adverse reactions associated with devil's claw use. These effects are generally mild and transient, often resolving spontaneously as the body adjusts to the medication. The bitter compounds in devil's claw stimulate gastric acid secretion, which explains why digestive disturbances are the most frequent complaint. Taking the capsules with food may help reduce gastrointestinal discomfort.

Allergic reactions, including skin rashes, urticaria (hives), and facial swelling, have been reported rarely. These may occur in individuals who are sensitive to devil's claw or to any of the excipients, particularly soy-derived components. If you experience any signs of an allergic reaction, such as difficulty breathing, swelling of the face, lips, tongue, or throat, or a widespread itchy rash, stop taking Giduxa immediately and seek medical attention.

Reporting Side Effects

Reporting suspected side effects after a medicine has been authorized is important. It helps with the continuous monitoring of the medicine's benefit-risk balance. Healthcare professionals and patients are encouraged to report suspected adverse reactions to their national medicines regulatory authority. In the EU, reports can be submitted through the national pharmacovigilance systems. In the UK, reports can be submitted via the Yellow Card Scheme. In the US, adverse events can be reported to the FDA MedWatch program.

How Should You Store Giduxa?

Quick Answer: Store Giduxa at or below 30°C. Keep out of the sight and reach of children. Do not use after the expiry date printed on the packaging.

Proper storage of medications is essential to maintain their quality, safety, and efficacy throughout their shelf life. Follow these guidelines for storing Giduxa capsules:

• Temperature: Store at or below 30°C (86°F). Do not refrigerate or freeze. Avoid exposing the capsules to excessive heat, such as leaving them in a car during hot weather or near a radiator.
• Light and moisture: Keep the capsules in their original blister packaging until ready to use. This helps protect them from light and moisture, which could degrade the active ingredients.
• Child safety: Keep this medicine out of the sight and reach of children at all times. Store in a secure location, preferably in a locked medicine cabinet.
• Expiry date: Do not use Giduxa after the expiry date (EXP) printed on the carton and blister pack. The expiry date refers to the last day of that month.

Do not dispose of medicines by flushing them down the toilet or putting them in household waste. Return unused or expired medicines to your local pharmacy for safe disposal. These measures help to protect the environment and prevent accidental ingestion.

What Does Giduxa Contain?

Quick Answer: Each Giduxa capsule contains 225 mg of dry extract from devil's claw root (equivalent to 990–1,125 mg dried root). The capsule also contains soybean oil, coconut oil, gelatin, glycerol, sorbitol, lactose, and soy lecithin.

Active Ingredient

The active substance in Giduxa is a dry extract from the root of devil's claw. Each soft capsule contains:

• 225 mg extract (as dry extract) from Harpagophytum procumbens DC. and/or Harpagophytum zeyheri Decne. (devil's claw), root
• Corresponding to 990–1,125 mg of dried devil's claw root
• Extraction solvent: ethanol 60% (v/v)

Other Ingredients (Excipients)

Physical Description

Giduxa capsules are oval (15 × 10 mm), light brown, soft capsules. The capsule contents are dark brown. The capsules are available in pack sizes of 30, 60, 90, and 120 capsules, although not all pack sizes may be marketed in every country.

Marketing Authorization Holder and Manufacturer

Marketing authorization holder: Sana Pharma Medical AS, Philip Pedersens vei 20, 1366 Lysaker, Norway.

Manufacturer: Aenova S.R.L., Str. Carol I nr. 1, RO-107180 Cornu, Romania.

References and Sources

This article is based on the following peer-reviewed sources and authoritative medical guidelines:

1. European Medicines Agency (EMA). European Union herbal monograph on Harpagophytum procumbens DC. and/or Harpagophytum zeyheri Decne., radix. Committee on Herbal Medicinal Products (HMPC). EMA/HMPC/627057/2015. Available at: ema.europa.eu
2. World Health Organization (WHO). WHO Monographs on Selected Medicinal Plants, Volume 3: Radix Harpagophyti. Geneva: WHO; 2007.
3. European Scientific Cooperative on Phytotherapy (ESCOP). ESCOP Monographs: Harpagophyti radix. 2nd ed. Stuttgart: Thieme; 2003.
4. Gagnier JJ, Chrubasik S, Manheimer E. Harpagophytum procumbens for osteoarthritis and low back pain: a systematic review. BMC Complement Altern Med. 2004;4:13. doi:10.1186/1472-6882-4-13
5. Chrubasik S, Conradt C, Roufogalis BD. Effectiveness of Harpagophytum extracts and clinical efficacy. Phytother Res. 2004;18(2):187-189. doi:10.1002/ptr.1416
6. Mncwangi N, Chen W, Vermaak I, et al. Devil's Claw — a review of the ethnobotany, phytochemistry and biological activity of Harpagophytum procumbens. J Ethnopharmacol. 2012;143(3):755-771. doi:10.1016/j.jep.2012.08.013
7. Brien S, Lewith GT, McGregor G. Devil's Claw (Harpagophytum procumbens) as a treatment for osteoarthritis: a review of efficacy and safety. J Altern Complement Med. 2006;12(10):981-993. doi:10.1089/acm.2006.12.981
8. Vlachojannis J, Roufogalis BD, Chrubasik S. Systematic review on the safety of Harpagophytum preparations for osteoarthritic and low back pain. Phytother Res. 2008;22(2):149-152. doi:10.1002/ptr.2314
9. National Institute for Health and Care Excellence (NICE). Osteoarthritis: care and management. Clinical Guideline CG177. Updated 2022.
10. Grant L, McBean DE, Fyfe L, Warnock AM. A review of the biological and potential therapeutic actions of Harpagophytum procumbens. Phytochem Rev. 2007;6:199-208. doi:10.1007/s11101-006-9032-y

Medical Editorial Team

This article has been written and reviewed by the iMedic Medical Editorial Team, consisting of licensed physicians and pharmacologists with expertise in clinical pharmacology, phytotherapy, and evidence-based medicine.

Editorial Policy: iMedic is committed to providing accurate, unbiased, and accessible medical information. All content is independently produced with no commercial funding or pharmaceutical sponsorship. Our editorial standards follow the principles of evidence-based medicine and are regularly audited for accuracy and completeness. For more information, visit our editorial standards page.